While an earlier meta-analysis suggested superior survival outcomes with PD-1 inhibitors compared to PD-L1 inhibitors in solid tumors [23], our study findings align with recent research indicating comparable efficacy of PD-1 and PD-L1 inhibitors in ES-SCLC patients. The gene discussed is PDCD1; the disease is small cell lung carcinoma.